Takeda

Redwood secures funding for drug development

Monday, July 11, 2011 12:46 PM

Redwood Bioscience has secured funding from Takeda Ventures to further develop its precision protein-chemical engineering platform for drug conjugate optimization.  This funding will be applied to advancing Redwood's site specific protein modification technology for enhancing antibody-drug conjugates and peptide therapeutics.  

More... »

Takeda acquires Nycomed

Thursday, May 19, 2011 10:45 AM

Japan-based Takeda Pharmaceutical has agreed to buy Switzerland-based Nycomed for $13.6 billion, making it a wholly-owned subsidiary of Takeda.

More... »

Takeda denies takeover of Nycomed

Friday, May 13, 2011 11:35 AM

Japan-based Takeda Pharmaceutical has denied rumors of a $12.3 billion takeover of Switzerland-based Nycomed, according to Pharma Times.

More... »

Takeda invests in Fate Therapeutics

Tuesday, May 10, 2011 12:22 PM

Japan-based Takeda has made a strategic investment in the U.S.-based Fate Therapeutics, a privately-held firm that specializes in stem cell research, according to Pharma Times.

More... »

Millenium expands on cancer treatment Velcade

Thursday, April 28, 2011 12:32 PM

Cambridge-based pharmaceutical company Millennium and their parent company Takeda Pharmaceutical, based in Japan, report they have submitted two supplemental new drug applications (NDAs) to the FDA for Velcade, a cancer treatment, according to Mass High Tech.

More... »

Takeda's Trevor Smith assumes role of CEO

Thursday, April 7, 2011 11:46 AM

Takeda Pharmaceutical’s Trevor Smith, currently vice president, International Strategy, will assume the role of chief executive officer of Takeda Pharmaceuticals Europe for oversight of pan-European sales and marketing.

More... »

Takeda, Amgen phase III motesanib trial fails

Friday, April 1, 2011 10:53 AM

Amgen, Takeda Pharmaceutical, and Millennium, a division of Takeda, announced unfavorable results from the MONET1 pivotal phase III trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival.

More... »

Millennium expands cancer pact with Seattle Genetics

Friday, March 18, 2011 01:43 PM

Takeda's Millennium has expanded its antibody-drug conjugate deal with Seattle Genetics, paying an undisclosed fee to exercise an option to designate a second antigen target outlined in their 2009 collaboration, according to Biosmart.

More... »

Amylin & Takeda suspend obesity trial

Friday, March 18, 2011 10:24 AM

Amylin Pharmaceuticals and Takeda Pharmaceutical have suspended clinical activities in an ongoing phase II study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

More... »

ITI, Takeda in collaboration

Thursday, March 3, 2011 02:40 PM

Intra-Cellular Therapies has entered into a preclinical discovery deal with Takeda to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia and a variety of psychiatric and neurological diseases, according to FierceBiotech.

More... »